Li Dingfeng, El Kawkgi Omar M, Henriquez Andres F, Bancos Irina
Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, MN, USA.
Gland Surg. 2020 Feb;9(1):43-58. doi: 10.21037/gs.2019.11.03.
Patients with hypercortisolism demonstrate high cardiovascular morbidity and mortality, especially if diagnosis is delayed. Hypercortisolism-induced cardiovascular and metabolic comorbidities include hypertension, impaired glucose metabolism, dyslipidemia, and obesity. High prevalence of cardiovascular risk factors leads to increased rate of cardiovascular events and mortality. This risk is reduced, albeit not reversed even after successful treatment of hypercortisolism. In this review we will describe prevalence and mechanisms of cardiovascular comorbidities in patients with hypercortisolism. In addition, we will summarize the effect of therapy on cardiovascular risk factors, events, as well as mortality.
皮质醇增多症患者表现出较高的心血管发病率和死亡率，尤其是在诊断延迟的情况下。皮质醇增多症引起的心血管和代谢合并症包括高血压、糖代谢受损、血脂异常和肥胖。心血管危险因素的高流行率导致心血管事件发生率和死亡率增加。即使在成功治疗皮质醇增多症后，这种风险也会降低，尽管不会完全消除。在这篇综述中，我们将描述皮质醇增多症患者心血管合并症的患病率和机制。此外，我们将总结治疗对心血管危险因素、事件以及死亡率的影响。
